Melanoma research is at an inflection point, where there has been considerable progress in unraveling biology and unprecedented advances in treatments. Critical unmet needs remain, however, in accurate detection and diagnosis; gaps in our understanding of how best to treat rare melanomas (acral, mucosal, uveal, and pediatric); and how to tackle treatment-resistant disease – especially brain metastasis and leptomeningeal disease.
MRA is uniquely prepared to change the melanoma research landscape once again by focusing on the following priority areas. Through collaboration of MRA’s world-class scientists and physicians, our generous donors, and the entire melanoma community, the time is now.
Acral, mucosal, pediatric, and uveal melanomas – what we collectively call rare melanomas – represent an area of profound unmet medical need. MRA is investing heavily to ensure patients facing these rare subtypes aren’t left behind, including the launch of our RARE Registry.
Although treatment options for advanced melanoma have improved, many patients either do not respond to treatment at all, or initially respond but then at a later point progress despite treatment. In either case, it is critical to identify new treatment options for this patient population.
Melanoma is the third most common source of brain metastases and has one of the highest rates of leptomeningeal disease. Considerable work is still needed to fully understand where central nervous system metastases originate and how they progress, in order to identify better treatment strategies.
Preventing melanoma, finding it as early as possible, and getting the right diagnosis from the start are critical to curbing rates of melanoma and ensuring optimal patient survival.
“What I love about MRA is that all the money goes to research. I have two friends who died of melanoma, so I know there is a lot more work to do, and I feel there is a reason I’m still here. Supporting MRA is something that I need to do now to help other patients with melanoma.”
